These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 25251053)

  • 41. Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) as a targeted cancer immunotherapy.
    Seimetz D; Lindhofer H; Bokemeyer C
    Cancer Treat Rev; 2010 Oct; 36(6):458-67. PubMed ID: 20347527
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Overexpression of the epithelial cell adhesion molecule is associated with a more favorable prognosis and response to platinum-based chemotherapy in ovarian cancer.
    Woopen H; Pietzner K; Richter R; Fotopoulou C; Joens T; Braicu EI; Mellstedt H; Mahner S; Lindhofer H; Darb-Esfahani S; Denkert C; Sehouli J
    J Gynecol Oncol; 2014 Jul; 25(3):221-8. PubMed ID: 25045435
    [TBL] [Abstract][Full Text] [Related]  

  • 43. IMT030122, A novel engineered EpCAM/CD3/4-1BB tri-specific antibody, enhances T-cell recruitment and demonstrates anti-tumor activity in mouse models of colorectal cancer.
    Shen J; Qian N; Xu G; Dou X; An Y; Yang C; Liu Y; Liu Y; Pan X; Wang J; Bai G; Chen H; Zhu X; Gao X; Zhou G; Xu Q
    Int Immunopharmacol; 2024 Aug; 137():112424. PubMed ID: 38878486
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A photosensitizer delivered by bispecific antibody redirected T lymphocytes enhances cytotoxicity against EpCAM-expressing carcinoma cells upon light irradiation.
    Blaudszun AR; Moldenhauer G; Schneider M; Philippi A
    J Control Release; 2015 Jan; 197():58-68. PubMed ID: 25449805
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class.
    Brischwein K; Parr L; Pflanz S; Volkland J; Lumsden J; Klinger M; Locher M; Hammond SA; Kiener P; Kufer P; Schlereth B; Baeuerle PA
    J Immunother; 2007; 30(8):798-807. PubMed ID: 18049331
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Microparticles from ovarian carcinomas are shed into ascites and promote cell migration.
    Press JZ; Reyes M; Pitteri SJ; Pennil C; Garcia R; Goff BA; Hanash SM; Swisher EM
    Int J Gynecol Cancer; 2012 May; 22(4):546-52. PubMed ID: 22315094
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Co-Stimulatory Bispecific Antibodies Induce Enhanced T Cell Activation and Tumor Cell Killing in Breast Cancer Models.
    Warwas KM; Meyer M; Gonçalves M; Moldenhauer G; Bulbuc N; Knabe S; Luckner-Minden C; Ziegelmeier C; Heussel CP; Zörnig I; Jäger D; Momburg F
    Front Immunol; 2021; 12():719116. PubMed ID: 34484225
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Potent inhibition of local and disseminated tumor growth in immunocompetent mouse models by a bispecific antibody construct specific for Murine CD3.
    Schlereth B; Kleindienst P; Fichtner I; Lorenczewski G; Brischwein K; Lippold S; da Silva A; Locher M; Kischel R; Lutterbüse R; Kufer P; Baeuerle PA
    Cancer Immunol Immunother; 2006 Jul; 55(7):785-96. PubMed ID: 16187083
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A multicenter phase 1 study of solitomab (MT110, AMG 110), a bispecific EpCAM/CD3 T-cell engager (BiTE®) antibody construct, in patients with refractory solid tumors.
    Kebenko M; Goebeler ME; Wolf M; Hasenburg A; Seggewiss-Bernhardt R; Ritter B; Rautenberg B; Atanackovic D; Kratzer A; Rottman JB; Friedrich M; Vieser E; Elm S; Patzak I; Wessiepe D; Stienen S; Fiedler W
    Oncoimmunology; 2018; 7(8):e1450710. PubMed ID: 30221040
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Heterodimeric bispecific single-chain variable-fragment antibodies against EpCAM and CD16 induce effective antibody-dependent cellular cytotoxicity against human carcinoma cells.
    Vallera DA; Zhang B; Gleason MK; Oh S; Weiner LM; Kaufman DS; McCullar V; Miller JS; Verneris MR
    Cancer Biother Radiopharm; 2013 May; 28(4):274-82. PubMed ID: 23611188
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A novel conditional active biologic anti-EpCAM x anti-CD3 bispecific antibody with synergistic tumor selectivity for cancer immunotherapy.
    Frey G; Cugnetti APG; Liu H; Xing C; Wheeler C; Chang HW; Boyle WJ; Short JM
    MAbs; 2024; 16(1):2322562. PubMed ID: 38445633
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The Biodistribution of a CD3 and EpCAM Bispecific T-Cell Engager Is Driven by the CD3 Arm.
    Suurs FV; Lorenczewski G; Stienen S; Friedrich M; de Vries EGE; de Groot DJA; Lub-de Hooge MN
    J Nucl Med; 2020 Nov; 61(11):1594-1601. PubMed ID: 32284393
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [T-cells activated with a trifunctional bi-specific antibody in head and neck cancer].
    Gronau S; Schmitt M; Reinhardt P; Wiesneth M; Riechelmann H
    Laryngorhinootologie; 2005 Nov; 84(11):822-8. PubMed ID: 16358189
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The impact of EpCAM expression on response to chemotherapy and clinical outcomes in patients with epithelial ovarian cancer.
    Tayama S; Motohara T; Narantuya D; Li C; Fujimoto K; Sakaguchi I; Tashiro H; Saya H; Nagano O; Katabuchi H
    Oncotarget; 2017 Jul; 8(27):44312-44325. PubMed ID: 28574829
    [TBL] [Abstract][Full Text] [Related]  

  • 55. New gene-immunotherapy combining TRAIL-lymphocytes and EpCAMxCD3 Bispecific antibody for tumor targeting.
    Groth A; Salnikov AV; Ottinger S; Gladkich J; Liu L; Kallifatidis G; Salnikova O; Ryschich E; Giese N; Giese T; Momburg F; Büchler MW; Moldenhauer G; Herr I
    Clin Cancer Res; 2012 Feb; 18(4):1028-38. PubMed ID: 22228630
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Characterization of a Novel Bispecific Antibody That Activates T Cells
    Chornoguz O; Leettola CN; Leander K; Brosnan K; Emmell E; Chiu ML; Santulli-Marotto S
    Monoclon Antib Immunodiagn Immunother; 2019 Dec; 38(6):242-254. PubMed ID: 31825302
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Targeting of cancer stem cell marker EpCAM by bispecific antibody EpCAMxCD3 inhibits pancreatic carcinoma.
    Salnikov AV; Groth A; Apel A; Kallifatidis G; Beckermann BM; Khamidjanov A; Ryschich E; Büchler MW; Herr I; Moldenhauer G
    J Cell Mol Med; 2009 Sep; 13(9B):4023-33. PubMed ID: 20196789
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Without prior stimulation, tumor-associated lymphocytes from malignant effusions lyse autologous tumor cells in the presence of bispecific antibody HEA125xOKT3.
    Strauss G; Gückel B; Wallwiener D; Moldenhauer G
    Clin Cancer Res; 1999 Jan; 5(1):171-80. PubMed ID: 9918216
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Treatment of non-small cell lung cancer patients with the trifunctional monoclonal antibody catumaxomab (anti-EpCAM x anti-CD3): a phase I study.
    Sebastian M; Passlick B; Friccius-Quecke H; Jäger M; Lindhofer H; Kanniess F; Wiewrodt R; Thiel E; Buhl R; Schmittel A
    Cancer Immunol Immunother; 2007 Oct; 56(10):1637-44. PubMed ID: 17410361
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Antitumor activity of an EpCAM/CD3-bispecific BiTE antibody during long-term treatment of mice in the absence of T-cell anergy and sustained cytokine release.
    Amann M; D'Argouges S; Lorenczewski G; Brischwein K; Kischel R; Lutterbuese R; Mangold S; Rau D; Volkland J; Pflanz S; Raum T; Münz M; Kufer P; Schlereth B; Baeuerle PA; Friedrich M
    J Immunother; 2009 Jun; 32(5):452-64. PubMed ID: 19609237
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.